HypoxyStat, a small-molecule form of hypoxia therapy that increases oxygen-hemoglobin affinity

Area of Science:

• Mitochondrial biology
• Neuroscience
• Pharmacology

Background:

• Chronic inhaled hypoxia shows therapeutic potential in animal models of mitochondrial Leigh syndrome.
• Existing gas-based therapies face challenges for clinical translation.
• Mitochondrial diseases, including Leigh syndrome, represent significant unmet medical needs.

Purpose of the Study:

• To evaluate a small molecule (HypoxyStat) as a clinically tractable alternative to inhaled hypoxia therapy.
• To determine if oral administration of HypoxyStat can mitigate disease progression in the Ndufs4 knockout mouse model of mitochondrial Leigh syndrome.
• To assess the efficacy of HypoxyStat in both preventing and reversing disease phenotypes.

Main Methods:

• Administration of HypoxyStat, a small molecule increasing hemoglobin-oxygen binding affinity, via daily oral dosing to Ndufs4 knockout mice.
• Assessment of lifespan, behavioral changes, body weight, body temperature, and neuropathology in treated and control mice.
• Induction of systemic hypoxia in mice breathing normoxic air through HypoxyStat treatment.

Main Results:

• Daily oral HypoxyStat administration significantly extended the lifespan of Ndufs4 knockout mice.
• Treatment rescued key disease aspects, including improved behavior, body weight, and body temperature.
• HypoxyStat demonstrated efficacy even when administered at late stages of the disease, reversing symptoms.
• The molecule induced systemic hypoxia in mice breathing normal air.

Conclusions:

• HypoxyStat represents a promising, orally available therapeutic agent for mitochondrial diseases.
• This small molecule effectively mimics the benefits of inhaled hypoxia therapy, overcoming delivery challenges.
• HypoxyStat offers a clinically tractable approach for treating mitochondrial Leigh syndrome and potentially other related conditions.